statements

Zenotech Laboratories Ltd.

BSE: 532039

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

45.00+0.7 (+1.60%)

27 Jul, 3:30 PM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Zenotech Laboratories Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	2.30	3.16	2.76	4.08	2.06	2.25	11.14	13.03	25.94	19.37	36.57	42.42	40.83	43.05	43.61
Cost of Operating Revenue	5.69	10.86	11.89	9.68	5.87	5.54	10.53	10.20	10.55	11.96	12.78	14.54	13.98	14.94	7.11
Gross Profit	-3.38	-7.70	-9.14	-5.60	-3.81	-3.29	0.61	2.83	15.39	7.42	23.78	27.89	26.85	28.11	36.50
Gross Margin	-147.0	-243.7	-331.6	-137.4	-184.9	-145.9	5.5	21.7	59.3	38.3	65.0	65.7	65.8	65.3	83.7
Total Operating Expenses	10.50	26.91	23.31	28.18	13.69	16.49	22.90	20.62	21.50	22.51	26.08	28.89	30.65	35.83	41.54
Operating Profit	-8.20	-23.75	-20.56	-24.11	-11.64	-14.24	-11.76	-7.59	4.44	-3.13	10.49	13.53	10.18	7.22	2.08
Operating Margin	-356.1	-751.4	-745.9	-591.3	-564.9	-631.7	-105.5	-58.3	17.1	-16.2	28.7	31.9	24.9	16.8	4.8
Financing Income/(Expense) - Net	-0.51	-1.62	-4.69	-6.65	-7.55	-7.51	-0.73	1.01	0.04	-1.49	-1.12	0.26	0.95	1.41	-
Profit before Taxes	-10.26	-25.52	-22.86	-30.41	-19.14	-19.87	-11.85	-3.13	10.78	-1.22	9.90	14.50	11.14	10.69	4.19
Income Taxes	-	-	-	-	-	-	-	-	-	-	-12.27	2.92	2.84	5.08	5.26
Profit after Tax	-10.26	-25.52	-22.86	-30.41	-19.14	-19.87	-11.85	-3.13	10.78	-1.22	22.18	11.59	8.30	5.61	-1.07
PAT Margin	-445.7	-807.5	-829.4	-746.1	-929.1	-881.4	-106.3	-24.0	41.6	-6.3	60.6	27.3	20.3	13.0	-2.5
EPS - Basic - ex Extraordinary Items	-2.83	-7.04	-6.30	-8.38	-5.28	-5.48	-1.94	-0.51	1.77	-0.20	3.63	1.90	1.36	0.92	-0.18
EPS - Diluted - ex Extraordinary Items	-2.83	-7.04	-6.30	-8.38	-5.28	-5.48	-1.94	-0.51	1.77	-0.20	3.63	1.90	1.36	0.92	-0.18
EBIT	-8.20	-23.75	-20.56	-24.11	-11.64	-14.24	-11.76	-7.59	4.44	-3.13	10.49	13.53	10.18	7.22	2.08
EBITDA	-4.71	-20.23	-17.00	-20.05	-7.67	-10.37	-7.86	-3.39	9.29	3.32	17.46	20.70	17.27	14.18	9.19
EBITDA Margin	-204.4	-640.1	-616.9	-491.8	-372.5	-459.8	-70.5	-26.0	35.8	17.2	47.8	48.8	42.3	32.9	21.1

Balance Sheet

Abridged

Understanding Balance Sheet

Zenotech Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	C 2015 Mar 31	C 2016 Mar 31	2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	2.55	4.55	10.80	8.48	2.53	1.82	31.42	19.19	5.71	7.35	7.37	16.26	26.16	35.99	41.04
Long-Term Investments	-	-	-	-	-	-	0.39	0.64	0.63	0.68	0.68	1.25	-	-	1.26
Property Plant & Equipment - Net	62.14	58.89	56.25	52.13	48.17	46.83	46.75	60.06	77.81	76.41	71.19	70.36	67.54	64.44	65.89
Total Non-Current Assets	65.88	62.45	59.39	55.23	50.39	48.93	50.32	65.39	79.85	78.50	86.71	84.61	80.04	75.04	70.11
Total Assets	68.44	67.00	70.19	63.71	52.92	50.75	81.74	84.58	85.55	85.84	94.08	100.87	106.21	111.03	111.15
Total Current Liabilities	16.47	40.26	66.36	90.44	98.78	116.42	39.45	45.35	35.44	14.95	15.58	16.61	13.52	12.59	12.06
Long Term Debt	0.09	0.16	0.08	0.04	0.01	-	-	-	-	20.66	6.00	-	-	-	-
Total Non-Current Liabilities	0.32	0.62	0.57	0.24	0.20	0.24	0.28	0.34	0.49	22.49	7.87	2.00	2.14	2.31	3.98
Total Liabilities	16.80	40.88	66.93	90.67	98.98	116.65	39.72	45.69	35.92	37.44	23.44	18.60	15.66	14.90	16.03
Total Shareholders' Equity	51.64	26.12	3.26	-26.96	-46.07	-65.91	42.02	38.90	49.63	48.41	70.64	82.27	90.54	96.13	95.12
Total Equity	51.64	26.12	3.26	-26.96	-46.07	-65.91	42.02	38.90	49.63	48.41	70.64	82.27	90.54	96.13	95.12
Total Liabilities & Equity	68.44	67.00	70.19	63.71	52.92	50.75	81.74	84.58	85.55	85.84	94.08	100.87	106.21	111.03	111.15

Cash Flow

Abridged

Understanding Cash Flow Statement

Zenotech Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	-4.79	-20.87	-15.10	-20.05	-6.96	-10.90	-24.38	-7.63	8.64	4.83	15.80	20.43	17.18	13.79	12.16
Working Capital - Increase/(Decrease)	3.08	10.22	-9.83	12.07	1.65	11.86	-8.75	-10.38	2.56	-0.59	0.76	0.49	-4.41	-2.89	-0.11
Net CF from Operating Activities	-1.71	-10.64	-24.92	-7.98	-5.30	0.95	-33.13	-18.01	11.20	4.25	16.55	20.92	12.77	10.90	12.04
Capital Expenditures - Net	0.12	0.47	0.94	0.03	0.01	0.71	3.82	18.03	21.75	4.91	1.94	6.19	4.23	3.86	8.32
Net CF from Investing Activities	-0.12	-0.47	-0.94	-0.03	5.21	-0.71	-4.38	-17.43	-21.73	-4.87	-1.94	-6.19	-22.10	13.88	-8.33
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	119.71	-	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	1.97	10.97	30.70	7.40	-0.02	-0.02	-54.28	20.24	-1.58	2.00	-14.66	-6.00	-	-	-
Net Cash Flow from Financing Activities	1.97	10.97	30.70	7.40	-0.04	-0.02	65.44	20.24	-1.58	2.00	-14.66	-6.00	-	-	-
Free Cash Flow to Equity	0.14	-0.15	4.83	-0.60	-5.33	0.23	-91.23	-15.81	-12.13	1.34	-0.04	8.73	8.54	7.03	3.72
Free Operating CF net dividend	-1.83	-11.37	-25.89	-8.03	-5.31	0.25	-36.95	-36.05	-10.55	-0.66	14.61	14.69	8.53	7.03	3.72
Free Operating CF	-1.83	-11.37	-25.89	-8.03	-5.31	0.25	-36.95	-36.05	-10.55	-0.66	14.61	14.69	8.53	7.03	3.72

Business Segment Analysis

FY End:

Mar 25

Zenotech Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 3.86 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 43.05 Cr

Assets

Pharmaceuticals (100.0%)₹ 111.03 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 7.22 Cr

Regional Segment Analysis

Zenotech Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Zenotech Laboratories Ltd.

Historical Segment Analysis

Track how Zenotech Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	4	18	22	5	2	6	4	4

Frequently Asked Questions

What is the revenue of Zenotech Laboratories Ltd.?

The latest trailing twelve month revenue of Zenotech Laboratories Ltd. is ₹ 43.61 Cr, reflecting a 1-year growth of 1.32% and a 3-year CAGR of 0.93%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Zenotech Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Zenotech Laboratories Ltd. is ₹ -1.07 Cr, with a 3-year earnings CAGR of -27.95%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Zenotech Laboratories Ltd.?

The trailing twelve month EBITDA of Zenotech Laboratories Ltd. is approximately ₹ 2.08 Cr (based on an operating margin of 4.76%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Zenotech Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Zenotech Laboratories Ltd. is -0.18. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Zenotech Laboratories Ltd.?

The debt-to-equity ratio of Zenotech Laboratories Ltd. stands at 0.00. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Zenotech Laboratories Ltd.?

The estimated book value per share of Zenotech Laboratories Ltd. is 15.67 (derived from a P/B ratio of 2.87 and market price of ₹ 45.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Zenotech Laboratories Ltd.?

The trailing twelve month operating cash flow of Zenotech Laboratories Ltd. is ₹ 12.04 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Zenotech Laboratories Ltd. report consolidated or standalone financials?

Zenotech Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.